In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cook's New Brew in AAA Grafts

Executive Summary

Sometime in the next year or so, Cook officials hope to enter the market for peripheral vascular grafts for abdominal aortic aneurysms, a highly competitive field currently attracting companies such as Medtronic Inc., Boston Scientific Corp. and Guidant Corrp., which last year purchased AAA leader Endovascular Technologies Inc.

You may also be interested in...



Cook's New Chef Tries a Different Recipe

Top management changes at Cook are bringing subtle shifts in the company's attitude towards the marketplace. John DeFord, who has been at the company for 15 years is now president and CEO of its interventional products business, replacing Phyllis McCollough, who moves up to Chairman and EVP of operations for all of Cook Group. DeFord is spearheading Cook's new, more aggressive, opportunistic approach. A noteworthy example: Cook is embarking on a series of distribution deals with a competitor, stent market leader Guidant.

Coronavirus Update: US Public Confidence In COVID-19 Vaccines Declines

Confidence in the vaccine has slipped in the US, regardless of political affiliation.

Janssen’s Amivantamab Combo Shows Promise In First-Line NSCLC

Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator. 

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel